Abstract:Introduction: Although many sepsis biomarkers have shown promise in selected patient groups, only C-reactive protein and procalcitonin (PCT) have entered clinical practice. The aim of this study was to evaluate three promising novel sepsis biomarkers in unselected patients at admission to intensive care. We assessed the performance of pancreatic stone protein (PSP), soluble CD25 (sCD25) and heparin binding protein (HBP) in distinguishing patients with sepsis from those with a non-infective systemic inflammatory response and the ability of these markers to indicate severity of illness. Methods: Plasma levels of the biomarkers, PCT and selected inflammatory cytokines were measured in samples taken from 219 patients during the first six hours of admission to intensive or high dependency care. Patients with a systemic inflammatory response were categorized as having sepsis or a non-infective aetiology, with or without markers of severity, using standard diagnostic criteria. Results: Both PSP and sCD25 performed well as biomarkers of sepsis irrespective of severity of illness. For both markers the area under the receiver operating curve (AUC) was greater than 0.9; PSP 0.927 (0.887 to 0.968) and sCD25 0.902 (0.854 to 0.949). Procalcitonin and IL6 also performed well as markers of sepsis whilst in this intensive care unit (ICU) population, HBP did not: PCT 0.840 (0.778 to 0.901), IL6 0.805 (0.739 to 0.870) and HBP 0.607 (0.519 to 0.694). Levels of both PSP and PCT reflected severity of illness and both markers performed well in differentiating patients with severe sepsis from severely ill patients with a non-infective systemic inflammatory response: AUCs 0.955 (0.909 to 1) and 0.837 (0.732 to 0.941) respectively. Although levels of sCD25 did not correlate with severity, the addition of sCD25 to either PCT or PSP in a multivariate model improved the diagnostic accuracy of either marker alone. Conclusions: PSP and sCD25 perform well as sepsis biomarkers in patients with suspected sepsis at the time of admission to intensive or high dependency care. These markers warrant further assessment of their prognostic value. Whereas previously published data indicate HBP has clinical utility in the emergency department, it did not perform well in an intensive-care population.

Towards improved point-of-care (POC) testing for patients with suspected sepsis: POC tests for host biomarkers and possible microbial pathogens

Added Diagnostic Value of Biomarkers in Patients with Suspected Sepsis: A Prospective Cohort Study in Out-Of-Hours Primary Care

AME Evidence Series 001-the Society for Translational Medicine: Clinical Practice Guidelines for Diagnosis and Early Identification of Sepsis in the Hospital

Role of procalcitonin use in the management of sepsis.

Rapid Detection of Sepsis: Recent Advances in Biomarker Sensing Platforms

Molecular and biomarker-based diagnostics in early sepsis: current challenges and future perspectives

Advancements and Clinical Applications—A Narrative Review

Analytical micro and nano technologies meet sepsis diagnosis

Microfluidics for sepsis early diagnosis and prognosis: a review of recent methods

Molecular antimicrobial susceptibility testing in sepsis

How to use biomarkers of infection or sepsis at the bedside: guide to clinicians

Diagnostic Accuracy of Point-Of-Care Testing of C-Reactive Protein, Interleukin-6, And Procalcitonin in Neonates with Clinically Suspected Sepsis: A Prospective Observational Study

Procalcitonin and sepsis in the Emergency Department: an update.

Getting Up to Speed: Rapid Pathogen and Antimicrobial Resistance Diagnostics in Sepsis

Electrochemical point-of-care devices for the diagnosis of sepsis

One biomarker does not fit all: tailoring anti-infective therapy through utilization of procalcitonin and other specific biomarkers

Sepsis biomarkers in unselected patients on admission to intensive or high-dependency care

A review of the value of point-of-care testing for community-acquired pneumonia

Real-world use of procalcitonin and other biomarkers among sepsis hospitalizations in the United States: A retrospective, observational study

The 'analysis of gene expression and biomarkers for point-of-care decision support in Sepsis' study; temporal clinical parameter analysis and validation of early diagnostic biomarker signatures for severe inflammation andsepsis-SIRS discrimination

Role of diagnostic tests for sepsis in children: a review